JUL 08, 2020 8:06 AM PDT

Tracking Down Biomarkers for Bladder Cancer Using Mass Spectrometry

WRITTEN BY: Jasper Cantrell

Bladder cancer is one of the most common cancers in the world. Non-muscle invasive bladder cancer (NMIBC) is a precursor that, when caught early, can give patients an incredibly favorable prognosis. However, if it advances into malignancy, the prognosis becomes uncertain, and treatments for it are considered some of the most expensive among cancer therapies.

Current diagnostic methods for NMIBC, such as cystoscopy, are invasive, expensive, and may not be able to find NMIBC in its early stages. Biomarker tests are common with many cancers and other diseases, but none of them have outperformed the more invasive methods. A team from a University in Saudi Arabia hypothesized that using Mass Spectrometry (MS) and a type of 2D-gel electrophoresis (2D-DIGE) could reliably use biomarkers to prognose NMIBC patients in a non-invasive way.

Both mass spectrometry and 2D-DIGE are tools used by researchers to separate and identify proteins in a sample. Recent advances have made them more useful outside of the lab, and many studies have begun trying to use them for diagnostic purposes. In theory, both methods combined could identify a profile of proteins for NMIBC patients versus healthy volunteers. This profile could then be applied to other patients, and feasibly diagnose bladder cancer.

They began by gathering blood samples from NMIBC positive patients and healthy volunteers. Using both methods, they identified three markers that were consistently changed in NMIBC samples versus healthy samples. The three markers were haptoglobin, ceruloplasmin, and complement component C6.
An in-depth literature search found studies linking all three markers were linked to bladder cancer. The team then tested the three-biomarker profile on another set of NMIBC and healthy patients. Haptoglobin was the most successful at diagnosing NMIBC patients. Ceruloplasmin and C6 were less so, but still mildly successful. In particular, ceruloplasmin had a unique change, but the team did not go beyond taking note of it in this study.

Biomarkers are the future of diagnostic tests for many diseases. They are non-invasive and could go as far as predicting a patient’s ten-year prognosis. For bladder cancer, most biomarker-based tests have yet to be successful enough to replace older methods. This study takes another step towards creating a practical biomarker test for bladder cancer and catching NMIBC before it becomes a problem.

The team concludes, “We believe that differential plasma proteome analysis of patients with low grade BC provides new insights on disease pathophysiology. The current study sheds the light on new plasma marker proteins that could potentially help in early detection of bladder cancer.”

Sources: Nature Scientific Reports, OncLive TV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 25, 2020
Cancer
Using Transcription Factors to Predict Bladder Cancer Prognosis
MAY 25, 2020
Using Transcription Factors to Predict Bladder Cancer Prognosis
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, wi ...
JUN 06, 2020
Cancer
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
JUN 06, 2020
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
Cancer has been one of the most persistent diseases modern medicine has faced. Due to its nature, treatments are often t ...
JUN 12, 2020
Cancer
Reserach on APOBEC3A opens the way for new treatment targets
JUN 12, 2020
Reserach on APOBEC3A opens the way for new treatment targets
New research identifies how a protein, APOBEC3A, triggers genetic changes that result in various cancers. This expansion ...
JUN 20, 2020
Cancer
A New MicroRNA Linked to the Suppression of Ovarian Cancer
JUN 20, 2020
A New MicroRNA Linked to the Suppression of Ovarian Cancer
One of the things a cancer patient can hear from their doctor is “recurrence.” Modern cancer therapies are a ...
JUL 01, 2020
Cancer
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
JUL 01, 2020
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
Angiogenesis is the vascularization, or generation of blood vessels, of a part of the body. It is a normal function of h ...
JUL 16, 2020
Immunology
Cancer Vaccine Charges Toward the Clinic
JUL 16, 2020
Cancer Vaccine Charges Toward the Clinic
Kristen Radford, a professor at Australia’s University of Queensland is among a scientific research team developin ...
Loading Comments...